アルツハイマー病における実行機能のための運動用量の最適化:ランダム化試験のベイジアン用量反応メタ解析
1Department of Sport and Leisure Studies, Hoseo University, Asan-si, South Korea.
Archives of gerontology and geriatrics
|August 29, 2025
まとめ
アルツハイマー病 (AD) の実行機能のための最適な運動には,用量反応関係があります. エアロビックトレーニングは670MET/min/weekで効果を示しているが,統合トレーニングは1200MET/min/weekが必要で,レジスタンストレーニングは一貫した結果を示していない.
科学分野:
- 神経科学
- 運動 生理学
- ゲロントロジー
背景:
- アルツハイマー病 (AD) は 実行機能を著しく低下させる.
- 身体的運動を含む非薬学的介入は,ADの管理に不可欠です.
- 効果的な認知能力の向上には 最適な運動量を知ることが重要です
研究 の 目的:
- アルツハイマー病 (AD) の患者に実行機能を改善するための最適な運動量範囲を決定する.
- エアロビック,統合体力トレーニング,レジスタンス運動の異なる運動様式における用量依存の認知反応プロファイルを比較する.
主な方法:
- 2025年6月20日までの5つの主要なデータベースで 体系的な文献検索
- 連続した用量反応曲線をモデル化するために使用されるベイジアンフレームワーク.
- ネットワークメタアナリシスで,様々なタイプの運動の相対的な効果を評価する.
主要な成果:
- 運動と実行機能の間の非線形的な用量反応関係が観察されました.
- 実行機能の改善に最適な効果は,週あたり1000MET分でした.
- 継続的な有酸素トレーニングは670MET-min/週で顕著な効果を示し,統合トレーニングは1200MET-min/週が必要であり,レジスタンストレーニングは有意な結果をもたらさなかった.
結論:
- 運動に基づく認知戦略の定量的な枠組みが確立されました.
- 運動量は,精度介入の方法と個々の能力に合わせて調整する必要があります.
- 最適な範囲 (670-1200 MET-min/week) はWHOの勧告と一致し,トランスレーションの可能性を示しています.
関連する概念動画
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:22Dose-Response Relationship: Potency and Efficacy
5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:03Dose-Response Relationship: Overview
3.7K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.7K
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:25Dose-Response Relationship: Selectivity and Specificity
8.1K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
8.1K